title: Efficacy of 2% ibopamine on the dilation of patients with pseudoexfoliation syndrome.
abstract: OBJECTIVE
  To compare the mydriatic effects of 2% ibopamine and collyrium containing 10% phenylephrine + 0.5% tropicamide and to study the associated drug in patients with ocular pseudoexfoliation (PEX) syndrome.
  
  
  METHODS
  This was a prospective, comparative, interventional clinical study. The study group consisted of 20 patients with ocular PEX syndrome. Intervention procedures included administration of 10% phenylephrine-0.5% tropicamide versus 2% ibopamine versus 2% ibopamine followed by the combination drug. Main outcome measurement was mydriatic efficacy measured in terms of mean pupil diameter. Adverse effects on intraocular pressure (IOP) were measured with a Goldmann applanation tonometer. Mean premedication pupil diameters in all patients were less than 3.5 mm.
  
  
  RESULTS
  Instillation of 10% phenylephrine-0.5% tropicamide caused significantly greater mydriasis than 2% ibopamine (pupil diameters: 6.17 mm, SD=1.14 versus 5.33 mm, SD=1.34; p<0.001). Combined use of both collyria significantly increased mydriasis (7.19 mm; SD=0.69) compared with that induced by either of the products alone (p<0.001). Inadequate mydriasis (pupil diameters < 5.5 mm) was observed in 2 patients after administration of 10% phenylephrine-0.5% tropicamide and in 10 following instillation of 2% ibopamine, but the addition of 10% phenylephrine -0.5% tropicamide to ibopamine-treated eyes resulted in adequate dilation in all cases. IOP increases of 4 mmHg over baseline values were observed in 12 (60%) patients after 2% ibopamine.
  
  
  CONCLUSIONS
  In patients with ocular PEX, instillation of 2% ibopamine exerts a significant additive effect on mydriasis induced with 10% phenylephrine-0.5% tropicamide with only minimal increases in IOP.
authors.affiliation: Department of Ophthalmology, S. Andrea Hospital, University of Roma Sapienza, Roma, Italy.
authors.forename: Gian Luca
authors.initials: GL
authors.lastname: Scuderi
authors.forename: Federico
authors.initials: F
authors.lastname: Regine
authors.forename: Andrea
authors.initials: A
authors.lastname: Perdicchi
authors.forename: Angela
authors.initials: A
authors.lastname: Turtoro
authors.forename: Maria Teresa
authors.initials: MT
authors.lastname: Contestabile
mesh_terms: D000368:Aged; D003846:Deoxyepinephrine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004338:Drug Combinations; D017889:Exfoliation Syndrome / Q000150:complications*; D005260:Female; D006801:Humans; D007429:Intraocular Pressure; D008297:Male; D009184:Mydriatics / Q000008:administration & dosage*; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D010656:Phenylephrine / Q000008:administration & dosage; D011446:Prospective Studies; D011680:Pupil / Q000187:drug effects*; D014065:Tonometry, Ocular; D016896:Treatment Outcome; D014331:Tropicamide / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; D009184:Mydriatics; D009883:Ophthalmic Solutions; D010656:Phenylephrine; C023487:ibopamine; D014331:Tropicamide; D003846:Deoxyepinephrine